Highest-materiality recent filing
RetinalGenix auditor Liebman Hymowitz resigns; Vilki & Co. appointed
Liebman Hymowitz resigned as auditor effective July 13, 2026; no disagreements with the company.
RetinalGenix CFO Michael Cory Zwerling resigns effective immediately
CFO Michael Cory Zwerling resigned effective immediately on March 22, 2026.
RetinalGenix amends warrant to bar exercise until 2030 or 3 yrs after uplisting
Amendment restricts exercise of 28,014,540-share pre-funded warrant held by Sanovas Ophthalmology, LLC.
RetinalGenix acquires DNA/GPS for 2M shares; combines retinal imaging with genetic mapping
Acquired all outstanding shares of DNA/GPS Inc. in exchange for 2,000,000 shares of RTGN common stock.
RetinalGenix exchanges 28M shares for pre-funded warrant; outstanding shares drop to 14.2M
Exchanged 28,014,540 shares held by Sanovas Ophth for a pre-funded warrant to purchase same number of shares at $0.0001 per share.
On December 4, 2023, the Board of Directors (the “Board”) of RetinalGenix Technologies Inc. (the ‘Company”) appointed Ms. Dessislava (Dessy) Boneva M.D. FACS, to serve as a director of the Company.
On November 30, 2023, the Board of Directors (the “Board”) of RetinalGenix Technologies Inc. (the ‘Company”) appointed Virender Ahluwalia to serve as Interim Chief Financial Officer of the Company.
On July 25, 2022, the Board of Directors (the “Board”) of RetinalGenix Inc. (the ‘Company”) appointed Vinay Mehindru, MD, MBA to serve as a director of the Company.
Max materiality 0.70 · Median 0.53 · Most common event leadership